Author:
Guan Jiaheng,Zhang Jing,Zhang Xiaoping,Yuan Zhongshu,Cheng Jian,Chen Baoan
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference58 articles.
1. Cancer statistics, 2022.;Siegel;CA Cancer J Clin,2022
2. The 2016 revision of the World Health Organization classification of lymphoid neoplasms.;Swerdlow;Blood,2016
3. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome.;Alsaab;Front Pharmacol,2017
4. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.;Chen;Blood,2019
5. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.;Shi;Lancet Haematol,2019
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献